CN1367003A - Medicine for curing AIDS - Google Patents
Medicine for curing AIDS Download PDFInfo
- Publication number
- CN1367003A CN1367003A CN02109950A CN02109950A CN1367003A CN 1367003 A CN1367003 A CN 1367003A CN 02109950 A CN02109950 A CN 02109950A CN 02109950 A CN02109950 A CN 02109950A CN 1367003 A CN1367003 A CN 1367003A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- rhizoma
- fructus
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 46
- 208000030507 AIDS Diseases 0.000 title claims abstract description 40
- 229940079593 drug Drugs 0.000 title description 4
- 239000008517 radix Trichosanthis Substances 0.000 claims abstract description 18
- 241000207929 Scutellaria Species 0.000 claims abstract description 3
- 238000011282 treatment Methods 0.000 claims description 24
- 208000011580 syndromic disease Diseases 0.000 claims description 17
- 241000190633 Cordyceps Species 0.000 claims description 16
- 241000756943 Codonopsis Species 0.000 claims description 15
- 241000628997 Flos Species 0.000 claims description 15
- 239000010231 banlangen Substances 0.000 claims description 15
- 210000000582 semen Anatomy 0.000 claims description 15
- 239000010135 fructus aurantii immaturus Substances 0.000 claims description 13
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 239000009636 Huang Qi Substances 0.000 claims description 9
- 241000605447 Anemarrhena Species 0.000 claims description 6
- 241000202755 Areca Species 0.000 claims description 6
- 241000555712 Forsythia Species 0.000 claims description 6
- 241000245240 Lonicera Species 0.000 claims description 6
- 241000545442 Radix Species 0.000 claims description 6
- 241001529553 Scoparia <angiosperm> Species 0.000 claims description 6
- 241000157835 Gardenia Species 0.000 claims description 4
- 230000036039 immunity Effects 0.000 abstract description 13
- 241000700605 Viruses Species 0.000 abstract description 7
- 238000002360 preparation method Methods 0.000 abstract description 4
- 244000247747 Coptis groenlandica Species 0.000 abstract 1
- 235000002991 Coptis groenlandica Nutrition 0.000 abstract 1
- 240000004670 Glycyrrhiza echinata Species 0.000 abstract 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 abstract 1
- 241000972673 Phellodendron amurense Species 0.000 abstract 1
- 235000017276 Salvia Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 abstract 1
- 229940010454 licorice Drugs 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 29
- 210000004369 blood Anatomy 0.000 description 27
- 239000008280 blood Substances 0.000 description 27
- 241000725303 Human immunodeficiency virus Species 0.000 description 26
- 230000006870 function Effects 0.000 description 21
- 230000000840 anti-viral effect Effects 0.000 description 13
- 230000001737 promoting effect Effects 0.000 description 11
- 230000036772 blood pressure Effects 0.000 description 10
- 210000004970 cd4 cell Anatomy 0.000 description 10
- 230000001603 reducing effect Effects 0.000 description 10
- 230000000259 anti-tumor effect Effects 0.000 description 9
- 230000003115 biocidal effect Effects 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 210000005259 peripheral blood Anatomy 0.000 description 9
- 239000011886 peripheral blood Substances 0.000 description 9
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 230000003110 anti-inflammatory effect Effects 0.000 description 8
- 210000000232 gallbladder Anatomy 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 230000000202 analgesic effect Effects 0.000 description 7
- 230000001093 anti-cancer Effects 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 208000004880 Polyuria Diseases 0.000 description 6
- 230000035619 diuresis Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 230000036592 analgesia Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 230000003266 anti-allergic effect Effects 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 210000004351 coronary vessel Anatomy 0.000 description 4
- 230000000916 dilatatory effect Effects 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 238000010926 purge Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000000812 cholinergic antagonist Substances 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002048 spasmolytic effect Effects 0.000 description 3
- 238000010025 steaming Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 206010007134 Candida infections Diseases 0.000 description 2
- 206010008631 Cholera Diseases 0.000 description 2
- 101800000115 Copeptin Proteins 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 239000004378 Glycyrrhizin Substances 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000000702 anti-platelet effect Effects 0.000 description 2
- 230000003471 anti-radiation Effects 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 230000000147 hypnotic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 230000008855 peristalsis Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 102000009660 Cholinergic Receptors Human genes 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 206010009152 Chronic tonsillitis Diseases 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- 208000003495 Coccidiosis Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- 201000011180 Dental Pulp Calcification Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 241000498255 Enterobius vermicularis Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 241000712469 Fowl plague virus Species 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 206010023076 Isosporiasis Diseases 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 229940118377 Vitamin antagonist Drugs 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 206010001093 acute tonsillitis Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001074 anti-adrenocortical effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000001572 anti-trichomonad Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 201000003486 coccidioidomycosis Diseases 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 208000001763 cytomegalovirus retinitis Diseases 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 206010014881 enterobiasis Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 206010033072 otitis externa Diseases 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000012858 packaging process Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000000590 parasiticidal effect Effects 0.000 description 1
- 239000002297 parasiticide Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002423 protozoacide Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 230000002557 soporific effect Effects 0.000 description 1
- 238000012859 sterile filling Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a medicine for resisting virus, raising immunity of human body and curing AIDS. Said medicine is a pure Chinese medicine preparation, and is made up by using 37 Chinese medicinal materials of licorice, radix trichosanthis, salvia root, dandelion herb, scutellaria root, coptis, phellodendron bark and others.
Description
Technical field:
The present invention relates to a kind of medicine for the treatment of acquired immune deficiency syndrome (AIDS), belong to the medicine of a kind of antiviral, raising body immunity.
Background technology:
Acquired immune deficiency syndrome (AIDS) is a kind of acquired immunodeficiency syndrome, it is the general infectious disease that causes by virus, often with lymphadenectasis, anorexia, chronic diarrhea, lose weight, heating, General Symptoms such as weak show, and progressively be developed to various opportunistic infection, secondary tumors, spirit neurological disorder etc. and dead is mainly passed through blood-borne.Do not have a kind of Western medicine or Chinese medicine can treat this disease at present, and can only slow down symptom, the proper extension life span, and this price that only works the medicine that slows down effect is expensive especially again, and most of patients does not have economic strength to bear.Therefore, arrived the what is said or talked about acquired immune deficiency syndrome (AIDS) at present, everybody gets degree by complexion changed, and people are afraid of acquired immune deficiency syndrome (AIDS), hide HIV sufferers, can only wait for death in case suffer from acquired immune deficiency syndrome (AIDS).
Summary of the invention:
The technical problem to be solved in the present invention is, a kind of low price, processing technique is simple, raw material is easy to get, has no side effect, can effectively treats acquired immune deficiency syndrome (AIDS) medicine are provided.
The present invention overcomes the above problems the technical scheme of taking to be: the medicine of this treatment acquired immune deficiency syndrome (AIDS) is mainly made by following component, Radix Glycyrrhizae 3-6 part, Radix Trichosanthis 3-6 part, Radix Salviae Miltiorrhizae 1-3 part, Herba Taraxaci 2-6 part, Radix Scutellariae 0.6-2 part, Rhizoma Coptidis 0.4-2 part, Cortex Phellodendri 0.4-2 part, Fructus Gardeniae 0.6-2 part, Rhizoma Zingiberis Recens 0.6-2 part, Rhizoma Anemarrhenae 1.2-2.4 part, Cortex Moutan 1.2-2.4 part, Cornu Bubali 3-6 part, Cornu rhinocerotis 0.2-0.6 part, Flos Lonicerae 2-3 part, Fructus Forsythiae 1.2-3 part, Rhizoma Smilacis Glabrae 3-12 part, Radix Et Rhizoma Rhei 1-2 part, Cortex Magnoliae Officinalis 0.6-2 part, Fructus Aurantii Immaturus 0.6-2 part, Rhizoma Alismatis 1.2-2.4 part, Herba Artemisiae Scopariae 2-6 part, Semen Arecae 1.2-2.4 part, Rhizoma Chuanxiong 0.6-2 part, Thallus Laminariae (Thallus Eckloniae) 1.2-2.4 part, Bulbus Allii 1-2 part, Radix Astragali 2-6 part, Radix Codonopsis 1.2-2.4 part, Radix Angelicae Sinensis 1.2-3 part, Radix Polygoni Multiflori 2-4 part, Radix Rehmanniae Preparata 1.8-4 part, Fructus Lycii 1.2-2.4 part, Fructus Jujubae 3-6 part, Fructus Hordei Germinatus 3-6 part, Cordyceps 1-2 part, Folium Isatidis 2-3 part, Radix Isatidis 2-3 part, Rhizoma Belamcandae 1.2-2 part.
The preferential scope of this medicine is: described Radix Glycyrrhizae 3.5-5.5 part, Radix Trichosanthis 3.5-5.5 part, Radix Salviae Miltiorrhizae 1.5-2.8 part, Herba Taraxaci 2.5-5.5 part, Radix Scutellariae 0.8-1.8 part, Rhizoma Coptidis 0.6-1.8 part, Cortex Phellodendri 0.6-1.8 part, Fructus Gardeniae 0.8-1.8 part, Rhizoma Zingiberis Recens 0.8-1.8 part, Rhizoma Anemarrhenae 1.4-2.2 part, Cortex Moutan 1.4-2.2 part, Cornu Bubali 3.5-5.5 part, Cornu rhinocerotis 0.25-0.55 part, Flos Lonicerae 2.2-2.8 part, Fructus Forsythiae 1.5-2.8 part, Rhizoma Smilacis Glabrae 3.5-11 part, Radix Et Rhizoma Rhei 1.2-1.8 part, Cortex Magnoliae Officinalis 0.8-1.8 part, Fructus Aurantii Immaturus 0.8-1.8 part, Rhizoma Alismatis 1.4-2.2 part, Herba Artemisiae Scopariae 2.5-5.5 part, Semen Arecae 1.4-2.2 part, Rhizoma Chuanxiong 0.8-1.8 part, Thallus Laminariae (Thallus Eckloniae) 1.4-2.2 part, Bulbus Allii 1.2-1.8 part, Radix Astragali 2.5-5.5 part, Radix Codonopsis 1.4-2.2 part, Radix Angelicae Sinensis 1.4-2.8 part, Radix Polygoni Multiflori 2.5-3.5 part, Radix Rehmanniae Preparata 2.5-3.5 part, Fructus Lycii 1.5-2.1 part, Fructus Jujubae 3.5-5.5 part, Fructus Hordei Germinatus 3.5-5.5 part, Cordyceps 1.3-1.8 part, Folium Isatidis 2.3-2.8 part, Radix Isatidis 2.3-2.8 part, Rhizoma Belamcandae 1.4-1.8 part.
Make at it and to have added Mel 3-6 part in component again.
Make at it and to have added nucleic acid 0.04-0.06 part in component again.
A kind of priority scheme is 3.5 parts in a described Radix Glycyrrhizae, 4 parts of Radix Trichosanthis, 2 parts of Radix Salviae Miltiorrhizaes, 2.5 parts of Herba Taraxacis, 0.8 part of Radix Scutellariae, 0.8 part of Rhizoma Coptidis, 1.8 parts of Cortex Phellodendris, 0.8 part of Fructus Gardeniae, 1 part in Rhizoma Zingiberis Recens, 2 parts of the Rhizoma Anemarrhenaes, 1.5 parts of Cortex Moutans, 4 parts of Cornu Bubalis, 0.25 part of Cornu rhinocerotis, 2.5 parts of Flos Loniceraes, 1.5 parts of Fructus Forsythiaes, 3.5 parts of Rhizoma Smilacis Glabraes, 1.5 parts of Radix Et Rhizoma Rhei, 0.8 part of Cortex Magnoliae Officinalis, 1 part of Fructus Aurantii Immaturus, 1.4 parts of Rhizoma Alismatis, 4 parts of Herba Artemisiae Scopariaes, 1.5 parts of Semen Arecaes, 1 part of Rhizoma Chuanxiong, 1.4 parts of Thallus Laminariae (Thallus Eckloniae)s, 1.5 parts in Bulbus Allii, 2.5 parts of the Radixs Astragali, 1.4 parts of Radix Codonopsis, 1.6 parts of Radix Angelicae Sinensis, 2.5 parts of Radix Polygoni Multiflori, 2.5 parts in Radix Rehmanniae Preparata, 1.5 parts of Fructus Lycii, 3.5 parts in Fructus Jujubae, 4 parts in Fructus Hordei Germinatus, 1.5 parts of Cordyceps, 2.3 parts of Folium Isatidiss, 2.5 parts of Radix Isatidis, 1.8 parts of Rhizoma Belamcandae, 4 parts of Mel.
Another kind of priority scheme is 5.5 parts in a described Radix Glycyrrhizae, 3.5 parts of Radix Trichosanthis, 2.8 parts of Radix Salviae Miltiorrhizaes, 5.5 parts of Herba Taraxacis, 1 part of Radix Scutellariae, 1.8 parts of Rhizoma Coptidis, 0.6 part of Cortex Phellodendri, 1.8 parts of Fructus Gardeniaes, 0.8 part in Rhizoma Zingiberis Recens, 2.2 parts of the Rhizoma Anemarrhenaes, 2 parts of Cortex Moutans, 5.5 parts of Cornu Bubalis, 0.45 part of Cornu rhinocerotis, 2.8 parts of Flos Loniceraes, 2.8 parts of Fructus Forsythiaes, 6 parts of Rhizoma Smilacis Glabraes, 1.2 parts of Radix Et Rhizoma Rhei, 1.4 parts of Cortex Magnoliae Officinalis, 1 part of Fructus Aurantii Immaturus, 2.2 parts of Rhizoma Alismatis, 2.5 parts of Herba Artemisiae Scopariaes, 2.2 parts of Semen Arecaes, 1.8 parts of Rhizoma Chuanxiongs, 1.6 parts of Thallus Laminariae (Thallus Eckloniae)s, 1.8 parts in Bulbus Allii, 3 parts of the Radixs Astragali, 2.2 parts of Radix Codonopsis, 1.4 parts of Radix Angelicae Sinensis, 3.5 parts of Radix Polygoni Multiflori, 2 parts in Radix Rehmanniae Preparata, 2.1 parts of Fructus Lycii, 5.5 parts in Fructus Jujubae, 3.5 parts in Fructus Hordei Germinatus, 1.3 parts of Cordyceps, 2.8 parts of Folium Isatidiss, 3 parts of Radix Isatidis, 1.4 parts of Rhizoma Belamcandae, 3.5 parts of Mel, 0.045 part of nucleic acid.
Another priority scheme is 4 parts in a described Radix Glycyrrhizae, 5.5 parts of Radix Trichosanthis, 1.5 parts of Radix Salviae Miltiorrhizaes, 3 parts of Herba Taraxacis, 1.8 parts of Radix Scutellariaes, 0.6 part of Rhizoma Coptidis, 0.6 part of Cortex Phellodendri, 1.4 parts of Fructus Gardeniaes, 1.8 parts in Rhizoma Zingiberis Recens, 1.4 parts of the Rhizoma Anemarrhenaes, 2.2 parts of Cortex Moutans, 3.5 parts of Cornu Bubalis, 0.55 part of Cornu rhinocerotis, 2.2 parts of Flos Loniceraes, 2 parts of Fructus Forsythiaes, 11 parts of Rhizoma Smilacis Glabraes, 1.8 parts of Radix Et Rhizoma Rhei, 1.8 parts of Cortex Magnoliae Officinalis, 1.8 parts of Fructus Aurantii Immaturuss, 1.8 parts of Rhizoma Alismatis, 5.5 parts of Herba Artemisiae Scopariaes, 1.4 parts of Semen Arecaes, 0.8 part of Rhizoma Chuanxiong, 2.2 parts of Thallus Laminariae (Thallus Eckloniae)s, 1.2 parts in Bulbus Allii, 5.5 parts of the Radixs Astragali, 1.8 parts of Radix Codonopsis, 2.8 parts of Radix Angelicae Sinensis, 3 parts of Radix Polygoni Multiflori, 3.5 parts in Radix Rehmanniae Preparata, 1.8 parts of Fructus Lycii, 4 parts in Fructus Jujubae, 5.5 parts in Fructus Hordei Germinatus, 1.8 parts of Cordyceps, 2.5 parts of Folium Isatidiss, 2.3 parts of Radix Isatidis, 2 parts of Rhizoma Belamcandae, 5.5 parts of Mel, 0.06 part of nucleic acid.
Because the present invention is a pure Chinese medicinal preparation, formulation components is Chinese herbal medicine entirely, and component compatibility is reasonable.Effect a permanent cure earlier in line with taking stopgap measures, based on comprehensively killing, antiviral as far as possible, it is auxilliary being healthy and strong with nourishing and fit keeping function, suitably selects to regulate the flow of vital energy, induces sweat, blood circulation promoting and blood stasis dispelling, antineoplastic Chinese medicinal components, comprehensive human body immunity improving power.And in antiviral Chinese medicinal components was selected, the Chinese medicinal components of anti AIDS virus at first again was as Radix Glycyrrhizae, Radix Salviae Miltiorrhizae, Radix Trichosanthis, Herba Taraxaci, Radix Scutellariae.This medicine has 19 kinds of sterilizations, antiviral component, and they are: Radix Trichosanthis, Herba Taraxaci, Radix Scutellariae, Rhizoma Coptidis, Cortex Phellodendri, Fructus Gardeniae, the Rhizoma Anemarrhenae, Cornu Bubali, Cornu rhinocerotis, Flos Lonicerae, Fructus Forsythiae, Folium Isatidis, Radix Isatidis, Rhizoma Belamcandae, Radix Et Rhizoma Rhei, Rhizoma Zingiberis Recens, Rhizoma Smilacis Glabrae, Semen Arecae, Cortex Moutan.
Radix Trichosanthis: have clearing away heat and promoting production of body fluid, evacuation of pus detumescence effect, a kind of albumen antiviral wherein, anti-AIDS.
Herba Taraxaci: have antibacterial, function of gallbladder promoting, diuresis, protect the liver, anticancer, the effect that suppresses HIV (human immunodeficiency virus) and human body immunity improving function.Its extracting solution has antagonism to endotoxin, and is a kind of direct destruction effect.
Radix Scutellariae: can suppress HIV (human immunodeficiency virus), regulate the Camp level, influence prostatic synthetic and metabolism, suppress lipid peroxidation.Also have antiinflammatory, antiallergic action, calmness, analgesic, anticancer, diuresis, blood pressure lowering, function of gallbladder promoting, spasmolytic, detoxifcation and effect for reducing blood fat.
Rhizoma Coptidis: staphylococcus, streptococcus, streptococcus pneumoniae, cholera are opened bacterium, anthrax bacillus etc. all have stronger antibacterial action, bacillus subtilis, pneumobacillus, diphtheria corynebacterium, bordetella pertussis, bacillus pestis, Brucella, tubercule bacillus are also had antibacterial action.Various popular susceptible poison, fowl plague virus, ameba, chlamydia trachomatis, infusorian, the graceful protozoon of the sharp meter in the torrid zone, trypanosomicide, blue trichobacteria, acrothesium floccosum, Canis familiaris L. sporidiole bacteria, starlike two card Salmonellas all there is inhibitory action.In addition, Rhizoma Coptidis also has effects such as blood pressure lowering, blood sugar lowering, anticancer, anti-radiation, heart tonifying, antidiarrheal, promotion organization healing.
Cortex Phellodendri: pathogenic fire purging, detoxifcation, clearing away damp-heat.Control otitis externa, rib adenitis, arthritis, dysentery, ulcer, skin itching.Hbs antigen had tangible choosing pool property inhibitory action.
Fructus Gardeniae: have function of gallbladder promoting, protect the liver, ease pain, calmness, blood pressure lowering, effect such as antibiotic.
The Rhizoma Anemarrhenae: heat clearing away, pathogenic fire purging, YIN nourishing, moisturize.
Cornu Bubali: heat clearing away, pathogenic fire purging, clear away heart-fire, removing heat from blood, detoxifcation.
Cornu rhinocerotis: heat clearing away, pathogenic fire purging, removing heat from blood, hemostasis, detoxifcation, arresting convulsion.
Flos Lonicerae: various pathogens is had inhibitory action, and antiinflammatory, analgesic, blood fat reducing, effects such as enhancing body defensive enginery are arranged.
Fructus Forsythiae: have antiviral, antibiotic, analgesic, effects such as tell in the town, diuresis, heart tonifying, blood pressure lowering and the damage of anti-liver.
Folium Isatidis: have significantly antibiotic, antiviral, antiinflammatory, effect such as analgesic.
Radix Isatidis: have antibiotic, antiviral, kill leptospira, promote functions such as immunity.
Rhizoma Belamcandae: have good refrigeration function, influenza virus, adenovirus, skin infection virus are had inhibitory action.
Radix Et Rhizoma Rhei: have rush down down, astringing to arrest bleeding, spasmolytic, function of gallbladder promoting, antibiotic, antiviral, parasiticide, antitumor, bring high blood pressure down, effects such as blood fat reducing, adjusting immunity and protection gastric mucosa.
Rhizoma Zingiberis Recens: have that the town tells, antiinflammatory, relieving cough and expelling phlegm, antibacterial, function of gallbladder promoting, antiplatelet aggregation, heart tonifying, an analgesia and promote effect such as gastric secretion.
Rhizoma Smilacis Glabrae: have antiinflammatory, antibacterial, antitumor, separate effects such as cotton powder poison.
Semen Arecae: have the body of killing worm, pinworm, ascarid, flagellate, fasciloopsis, ancylostome, inhibition dermatophytes, influenza virus, excited cholinoceptor, promote the dried glandular secretion of saliva, increase enterokinesia, decreasing heart rate, bring high blood pressure down, dwindle pupil, suppress effects such as mice ehrlich carcinoma.
Cortex Moutan: have calmness, hypnosis, analgesia, convulsion, blood pressure lowering, antibiotic, antiviral effect.
The strengthening by means of tonics medicine mainly contains 11 kinds: Radix Glycyrrhizae, Radix Angelicae Sinensis, the Radix Astragali, Radix Codonopsis, Radix Polygoni Multiflori, Radix Rehmanniae Preparata, Cordyceps, Fructus Lycii, Fructus Jujubae, Mel, nucleic acid.
Radix Glycyrrhizae: Radix Glycyrrhizae has anti-adrenocortical hormone, antiinflammatory, antiviral and antiallergic action, antitumor, relieving cough and expelling phlegm, analgesia, detoxifcation, anticonvulsant action.Protect the liver in addition, analgesic, antiulcer, spasmolytic, gastric acid inhibitory secretion, blood fat reducing and Radix Glycyrrhizae Copeptin, the glycyrrhizin regulated in the immunologic function, particularly Radix Glycyrrhizae have the obvious suppression effect to HIV (human immunodeficiency virus).
Radix Angelicae Sinensis: have coronary artery dilator, coronary blood flow increasing, reduce myocardial oxygen consumption, reduce platelet aggregation, antithrombotic formation, antitumor, improve the glomerular filtration function, effects such as blood fat reducing, antiinflammatory, analgesia, vitamin antagonist E deficiency disease, anti-anemia.And Radix Angelicae Sinensis also has very immune widely pharmacological action.
The Radix Astragali: have enhancing human body immunity function, heart tonifying, diuresis, anti-liver damage, infection, antiviral, antitumor, defying age, enhancing small intestinal peristalsis, effects such as resisting fatigue, anti-hypoxia, radioprotective, blood vessel dilating.
Radix Codonopsis: have rising blood glucose, anti-hypoxia, make the huge effects such as thin race quantity increases, resists myocardial ischemia of sneering.
Radix Polygoni Multiflori: have blood fat reducing, blood sugar lowering, antibiotic, heart tonifying, raise immunity, nourishing the brain and improving intelligence, defying age, effect such as protect the liver.
Radix Rehmanniae Preparata: have heart tonifying, blood sugar lowering and certain bacteriostasis.Funguses such as trichophyton mentagrophytes, ulotrichy denticle tinea bacterium all there is inhibitory action.
Fructus Lycii: have enhancing non-specific immunity function, anticancer, hemopoietic, promotion growth, blood fat reducing, protect the liver, blood sugar lowering, bring high blood pressure down and effect such as excited intestinal growth stimulation.
Cordyceps: have relieving asthma, blood pressure lowering, antitumor, antibiotic, eliminate the phlegm, effect such as calmness, convulsion, antiviral, defying age, blood sugar lowering, arrhythmia.Cordyceps polysaccharide (CP) has the dual regulation that makes immunostimulant or weaken to the body cell immunity, especially the T cell function is modulability influence.Its immune activation effect can obviously prolong life, protects the function of kidney in addition.
Fructus Jujubae: have the reduction serum cholesterol, increase total serum protein and albumin, antiallergic, press down that cancer is anticancer, tranquilizing soporific, blood sugar lowering, strengthen myocardial contraction, regulate immunologic function, strongly protect the liver, effect such as relieving cough and expelling phlegm.
Mel: have antitumor and remarkable inhibiting effect on tumor metastasis, and effects such as antibacterial, sterilization, blood sugar lowering, blood pressure lowering, detoxifcation, enhance immunity, promotion small intestinal peristalsis.
Nucleic acid: nucleic acid can improve immunologic function.
Diaphoretic medicine mainly contains Bulbus Allii and Fructus Hordei Germinatus.
Bulbus Allii: have effects such as antibiotic, protozoacide, anti-trichomonal, antitumor, blood fat reducing, blood pressure lowering, antiplatelet aggregation, atherosclerosis, delaying decrepitude of skin, removing free radical, supplementing the brain.
Fructus Hordei Germinatus: have aid digestion, promote gastric acid and pepsic secretion, blood sugar lowering, the effect of inhibition platelet aggregation.
QI regulating medicine mainly contains Fructus Aurantii Immaturus, Cortex Magnoliae Officinalis.
Fructus Aurantii Immaturus: have dispelling the stagnated QI removing food stagnancy, circulation of qi promoting except that the painful abdominal mass effect
Cortex Magnoliae Officinalis: QI invigorating, antiinflammatory, control cholera and stomachache.Expectorant, remove hydrops, aid digestion, hypnosis and sedation.
The drug for invigorating blood circulation and eliminating stasis Rhizoma Chuanxiong.Rhizoma Chuanxiong: have heart tonifying, increase coronary flow, coronary artery dilating, reduction myocardial oxygen consumption, blood pressure lowering, antithrombotic, antiallergic, anticancer, remove oxygen-derived free radicals, suppress platelet, activation, microcirculation improvement, calmness, anti-radiation function.
Preventing phlegm from forming and stopping coughing medicine Thallus Laminariae (Thallus Eckloniae).Thallus Laminariae (Thallus Eckloniae): have antitumor, blood sugar lowering, relieving asthma, antitussive, obviously promote body's immunity, obviously reduce serum cholesterol, microcirculation improvement obstacle and persistent hypotensive effect.
The function of gallbladder promoting hepatoprotective has Herba Artemisiae Scopariae, Rhizoma Alismatis.
Herba Artemisiae Scopariae: have function of gallbladder promoting, protect the liver, blood fat reducing, coronary artery dilating, blood pressure lowering, analgesic, kill ascarid and antibacterial action.
Rhizoma Alismatis: have effects such as blood fat reducing, anti-fatty liver, coronary artery dilating, diuresis, blood sugar lowering.
The comprehensive above all components of this medicine make its coordinative role, have anti AIDS virus, detumescence, consumer edema, analgesia, anticancer and chemotherapy function.Function with treating acute and chronic upper respiratory tract infection, acute/chronic bronchitis, stomatitis, acute and chronic tonsillitis, light-duty pneumonia, pharyngalgia, cough, blood circulation and channel invigorating.Have and control malaise, control the negative function with positive bacteria, acid fast bacteria, antibacterial, fungus of the blue formula of leather.Have that toxin expelling row is rushed down, the function of gallbladder promoting diuresis, increase the division of TB cytoactive and irritation cell, make that inhibin increases, increases CD4 lymphocyte peripheral blood quantity, QI invigorating, spleen invigorating, nourishes blood, hemopoietic function, human body immunity improving power comprehensively.Radix Glycyrrhizae Copeptin, the glycyrrhizin in the component particularly, a kind of albumen in the Radix Trichosanthis can make the virus increment more than 98% be suppressed.In addition, this medicine is in the symptom of improving the HIV/AIDS whole body, and is analgesic, to remove aspects such as weak, treatment diarrhoea particularly remarkable.Clinical treatment 120 routine HIV (human immunodeficiency virus) patients show that the effective percentage of this medicine has reached 100%, and obvious effective rate reaches 92%, and cure rate reaches 66,6%.
Clinical treatment 120 routine HIV (human immunodeficiency virus) patient's situation explanations
1 patient selects: 78 of male patients, account for 65%, and 42 of female patients account for 35%, and wherein 8-15 year patient is 15, accounts for 105 of 12.5%, 20 to 55 years old patients, accounts for 87,5%.
2, the diagnostic criteria of disease:
Every have one of following symptom person promptly to be diagnosed as to suffer from acquired immune deficiency syndrome (AIDS):
1. laboratory has been made a definite diagnosis HIV (human immunodeficiency virus) (HIV) and has been infected, and is less than 200 or CD4 lymphocyte with every cubic millimeter of blood cd4 cell number and is lower than 14%.
2. laboratory has made a definite diagnosis that HIV (human immunodeficiency virus) (HIV) infects and with following clinical manifestation person.Bronchus and trachea pulmonary candidiasis infect, the esophagus monilial infection, the wellability cervical cancer, dissemination and coccidioidomycosis of lung, the outer coccidiosis of lung, non-liver, spleen and lymph-node cell virus disease, with the cytomegaloviral retinitis of visual loss, the chronic ulcer that HIV (human immunodeficiency virus) dependency encephalopathy, simple scar exanthema virus cause.
3, treatment standard: the regulation according to present treating AIDS standard is carried out.Be any medicine or therapy as long as the every microlitre peripheral blood increase of patient's cd4 cell number is judged to more than 50 effectively, otherwise be invalid.If being increased to, patient's the every microlitre peripheral blood of cd4 cell number then is produce effects more than 140.Infect if treatment made the patient not have human immunity defective virus (HIV) to a year and a half in 1 year, every cubic millimeter of blood cd4 cell number is higher than 20% greater than 200 or CD4 lymphocyte.
4, the treatment course of treatment and method of administration:
1., treat the course of treatment: two months is a course of treatment.
2., method of administration: obey each 3g (no matter be among its 3g of tablet, decoction, electuary or capsule active component be identical) every day 3 times
5, therapeutic outcome; Totally 120 of the patients who receives treatment take this medicine after 8 weeks, and the every microlitre peripheral blood of its cd4 cell number has all increased more than 100, and what have has reached 145, and effective percentage is 100%.Have 110 patients to take this medicine after 12 weeks, the every microlitre peripheral blood of its cd4 cell number has on average increased more than 185.Obvious effective rate is 92%.HIV (human immunodeficiency virus) (HIV) the infection disappearance after 1 year of 80 patient treatments is arranged, and every microlitre peripheral blood cd4 cell number has on average reached more than 256, the CD4 lymphocyte has on average reached more than 20%.Cure rate reaches 66,6%.See treatment statistical result table for details:
Treatment statistical result table:
| Patient's number | Take medicine after 8 weeks | Take medicine after 12 weeks | After taking medicine 1 year | ||||||||
| Every microlitre peripheral blood cd4 cell number | Therapeutic outcome percent | Every microlitre peripheral blood cd4 cell number | Therapeutic outcome percent | Every microlitre peripheral blood cd4 cell number | CD4 lymphocyte number % | Therapeutic outcome percent | |||||
| 120 | The man | 78 account for 65 % | 8-1 5 years old | 8 | ?100-145 | ?100 ?％ | ??185-200 | ?92％ | 256-310 | ?22-25 | ??66.6 ??％ |
| 20-55 years old | 70 | ??80-100 | ??185-191 | ?256-300 | ?20-28 | ||||||
| The woman | 42 account for 35 % | 8-1 5 years old | 7 | ??100-145 | ??185-200 | ?256-310 | ?21-26 | ||||
| 20-55 years old | 25 | ??80-115 | ??185-195 | ?256-305 | ?22-30 | ||||||
The specific embodiment:
Manufacture process below in conjunction with this medicine provides embodiments of the invention, is used for further specifying technical solution.
Embodiment 1: desire is made the oral medicine liquor with 781.5 kilograms of raw materials.Its raw material and preparation method are as follows:
1, weighing component: at first take by weighing clean, pure Radix Glycyrrhizae 35kg, Radix Trichosanthis 40kg, Radix Salviae Miltiorrhizae 20kg, Herba Taraxaci 25kg, Radix Scutellariae 8kg, Rhizoma Coptidis 8kg, Cortex Phellodendri 18kg, Fructus Gardeniae 8kg, Rhizoma Zingiberis Recens 10kg, Rhizoma Anemarrhenae 20kg, Cortex Moutan 15kg, Cornu Bubali 40kg, Cornu rhinocerotis 2.5kg, Flos Lonicerae 25kg, Fructus Forsythiae 15kg, Rhizoma Smilacis Glabrae 35kg, Radix Et Rhizoma Rhei 15kg, Cortex Magnoliae Officinalis 8kg, Fructus Aurantii Immaturus 10kg, Rhizoma Alismatis 14kg, Herba Artemisiae Scopariae 40kg, Semen Arecae 15kg, Rhizoma Chuanxiong 10kg, Thallus Laminariae (Thallus Eckloniae) 14kg, Bulbus Allii 15kg, Radix Astragali 25kg, Radix Codonopsis 14kg, Radix Angelicae Sinensis 16kg, Radix Polygoni Multiflori 25kg, Radix Rehmanniae Preparata 25kg, Fructus Lycii 15kg, Fructus Jujubae 35kg, Fructus Hordei Germinatus 40kg, Cordyceps 15kg, Folium Isatidis 23kg, Radix Isatidis 25kg, Rhizoma Belamcandae 18kg, Mel 40kg.2, for the first time decoct medicinal liquid: with Radix Trichosanthis 40kg, Radix Salviae Miltiorrhizae 20kg, Herba Taraxaci 25kg, Radix Scutellariae 8kg, Rhizoma Coptidis 8kg, Cortex Phellodendri 18kg, Fructus Gardeniae 8kg, Rhizoma Zingiberis Recens 10kg, Rhizoma Anemarrhenae 20kg, Cortex Moutan 15kg, Flos Lonicerae 25kg, Fructus Forsythiae 15kg, Rhizoma Smilacis Glabrae 35kg, Cortex Magnoliae Officinalis 8kg, Fructus Aurantii Immaturus 10kg, Rhizoma Alismatis 14kg, Herba Artemisiae Scopariae 40kg, Semen Arecae 15kg, Rhizoma Chuanxiong 10kg, Thallus Laminariae (Thallus Eckloniae) 14kg, Folium Isatidis 23kg, Radix Isatidis 25kg, Rhizoma Belamcandae 18kg, Cornu rhinocerotis 2.5kg, 25 flavor Chinese medicines such as Radix Et Rhizoma Rhei 15kg are put into the container of boiling medicine, in container, pour enough water into, decoct 2-3 time with fire, every all over enduring 20-30 minute, get 2-3 filtrate and mix homogeneously, it is stand-by to put into a container.3, decoct medicinal liquid for the second time: with Radix Glycyrrhizae 35kg, Cornu Bubali 40kg, Radix Astragali 25kg, Radix Codonopsis 14kg, Radix Angelicae Sinensis 16kg, Radix Polygoni Multiflori 25kg, Radix Rehmanniae Preparata 25kg, Fructus Lycii 15kg, Fructus Jujubae 35kg, Fructus Hordei Germinatus 40kg, 12 flavor Chinese medicines such as Bulbus Allii 15kg, Cordyceps 15kg are put into the container of boiling medicine, inject suitable quantity of water in the phase container, decoct 3 times, each 1-1.2 hour, get 3 times decoction filtrate, pour into then and fried in shallow oil in well-done 25 flavors in the drug filtrate.4, Mel steaming and decocting and medicinal liquid mix: Mel 40kg was put into the steamer steaming and decocting 20-30 minute, mix with herb liquid then, the fiery transpiring moisture of reuse temperature makes it be concentrated to 350kg, adds an amount of additive, to regulate taste.5, sterile filling of bottles with.
Embodiment 2: desire is made the capsule shape medicine with 959.95 kilograms of raw materials.Its raw material and preparation method are as follows:
1, at first take by weighing clean, pure Radix Glycyrrhizae 55kg, Radix Trichosanthis 35kg, Radix Salviae Miltiorrhizae 28kg, Herba Taraxaci 55kg, Radix Scutellariae 10kg, Rhizoma Coptidis 18kg, Cortex Phellodendri 6kg, Fructus Gardeniae 18kg, Rhizoma Zingiberis Recens 8kg, Rhizoma Anemarrhenae 22kg, Cortex Moutan 20kg, Cornu Bubali 55kg, Cornu rhinocerotis 4.5kg, Flos Lonicerae 28kg, Fructus Forsythiae 28kg, Rhizoma Smilacis Glabrae 60kg, Radix Et Rhizoma Rhei 12kg, Cortex Magnoliae Officinalis 14kg, Fructus Aurantii Immaturus 10kg, Rhizoma Alismatis 22kg, Herba Artemisiae Scopariae 25kg, Semen Arecae 22kg, Rhizoma Chuanxiong 18kg, Thallus Laminariae (Thallus Eckloniae) 16kg, Bulbus Allii 18kg, Radix Astragali 30kg, Radix Codonopsis 22kg, Radix Angelicae Sinensis 14kg, Radix Polygoni Multiflori 35kg, Radix Rehmanniae Preparata 20kg, Fructus Lycii 21kg, Fructus Jujubae 55kg, Fructus Hordei Germinatus 35kg, Cordyceps 13kg, Folium Isatidis 28kg, Radix Isatidis 30kg, Rhizoma Belamcandae 14kg, Mel 35kg, nucleic acid 0.45kg.The back 2, for the first time decoct medicinal liquid, 3, decoct medicinal liquid for the second time, identical with embodiment 1.Its distinctive points is: 1. added nucleic acid 0.45kg in the Mel steaming and decocting of the 4th road manufacturing procedure and medicinal liquid mix, and stirred with it.2. because medicine is to exist according to capsule form, thus the bottling disinfecting steps of embodiment 1 removed, and increased following operation.A, medical starch and medicinal liquid mixed processes must mix medicinal liquid with medical starch in this operation by a certain percentage.Powdery and sterilization are dried, made to B, oven dry and sterilization process by this operation with medicine.C, encapsulated and packaging process.By this operation powdered drug is incapsulated and to form capsule in the shell, and be one to pack by per 18.Compare the processing technique complexity with embodiment 1, but taking convenience.
The technical solution that in like manner, provides according to the present invention can also provide each constituent content with more than
Embodiment is identical, but medicament is the embodiment of tablet, honey pill agent.Or each constituent content difference,
The embodiment that pharmaceutically dosage form is identical or different.
Claims (8)
1, a kind of medicine for the treatment of acquired immune deficiency syndrome (AIDS) is characterized in that it mainly contains following component and makes, Radix Glycyrrhizae 3-6 part, Radix Trichosanthis 3-6 part, Radix Salviae Miltiorrhizae 1-3 part, Herba Taraxaci 2-6 part, Radix Scutellariae 0.6-2 part, Rhizoma Coptidis 0.4-2 part, Cortex Phellodendri 0.4-2 part, Fructus Gardeniae 0.6-2 part, Rhizoma Zingiberis Recens 0.6-2 part, Rhizoma Anemarrhenae 1.2-2.4 part, Cortex Moutan 1.2-2.4 part, Cornu Bubali 3-6 part, Cornu rhinocerotis 0.2-0.6 part, Flos Lonicerae 2-3 part, Fructus Forsythiae 1.2-3 part, Rhizoma Smilacis Glabrae 3-12 part, Radix Et Rhizoma Rhei 1-2 part, Cortex Magnoliae Officinalis 0.6-2 part, Fructus Aurantii Immaturus 0.6-2 part, Rhizoma Alismatis 1.2-2.4 part, Herba Artemisiae Scopariae 2-6 part, Semen Arecae 1.2-2.4 part, Rhizoma Chuanxiong 0.6-2 part, Thallus Laminariae (Thallus Eckloniae) 1.2-2.4 part, Bulbus Allii 1-2 part, Radix Astragali 2-6 part, Radix Codonopsis 1.2-2.4 part, Radix Angelicae Sinensis 1.2-3 part, Radix Polygoni Multiflori 2-4 part, Radix Rehmanniae Preparata 1.8-4 part, Fructus Lycii 1.2-2.4 part, Fructus Jujubae 3-6 part, Fructus Hordei Germinatus 3-6 part, Cordyceps 1-2 part, Folium Isatidis 2-3 part, Radix Isatidis 2-3 part, Rhizoma Belamcandae 1.2-2 part.
2, the medicine of treatment acquired immune deficiency syndrome (AIDS) according to claim 1 is characterized in that described Radix Glycyrrhizae 3.5-5.5 part, Radix Trichosanthis 3.5-5.5 part, Radix Salviae Miltiorrhizae 1.5-2.8 part, Herba Taraxaci 2.5-5.5 part, Radix Scutellariae 0.8-1.8 part, Rhizoma Coptidis 0.6-1.8 part, Cortex Phellodendri 0.6-1.8 part, Fructus Gardeniae 0.8-1.8 part, Rhizoma Zingiberis Recens 0.8-1.8 part, Rhizoma Anemarrhenae 1.4-2.2 part, Cortex Moutan 1.4-2.2 part, Cornu Bubali 3.5-5.5 part, Cornu rhinocerotis 0.25-0.55 part, Flos Lonicerae 2.2-2.8 part, Fructus Forsythiae 1.5-2.8 part, Rhizoma Smilacis Glabrae 3.5-11 part, Radix Et Rhizoma Rhei 1.2-1.8 part, Cortex Magnoliae Officinalis 0.8-1.8 part, Fructus Aurantii Immaturus 0.8-1.8 part, Rhizoma Alismatis 1.4-2.2 part, Herba Artemisiae Scopariae 2.5-5.5 part, Semen Arecae 1.4-2.2 part, Rhizoma Chuanxiong 0.8-1.8 part, Thallus Laminariae (Thallus Eckloniae) 1.4-2.2 part, Bulbus Allii 1.2-1.8 part, Radix Astragali 2.5-5.5 part, Radix Codonopsis 1.4-2.2 part, Radix Angelicae Sinensis 1.4-2.8 part, Radix Polygoni Multiflori 2.5-3.5 part, Radix Rehmanniae Preparata 2.5-3.5 part, Fructus Lycii 1.5-2.1 part, Fructus Jujubae 3.5-5.5 part, Fructus Hordei Germinatus 3.5-5.5 part, Cordyceps 1.3-1.8 part, Folium Isatidis 2.3-2.8 part, Radix Isatidis 2.3-2.8 part, Rhizoma Belamcandae 1.4-1.8 part.
3, the medicine of treatment acquired immune deficiency syndrome (AIDS) according to claim 1 and 2 is characterized in that, makes at it to have added Mel 3-6 part in component again.
4, the medicine of treatment acquired immune deficiency syndrome (AIDS) according to claim 1 and 2 is characterized in that, makes at it to have added nucleic acid 0.04-0.06 part in component again.
5, the medicine of treatment acquired immune deficiency syndrome (AIDS) according to claim 3 is characterized in that, makes at it to have added nucleic acid 0.04-0.06 part in component again.
6, the medicine of treatment acquired immune deficiency syndrome (AIDS) according to claim 3 is characterized in that 3.5 parts in described Radix Glycyrrhizae, 4 parts of Radix Trichosanthis, 2 parts of Radix Salviae Miltiorrhizaes, 2.5 parts of Herba Taraxacis, 0.8 part of Radix Scutellariae, 0.8 part of Rhizoma Coptidis, 1.8 parts of Cortex Phellodendris, 0.8 part of Fructus Gardeniae, 1 part in Rhizoma Zingiberis Recens, 2 parts of the Rhizoma Anemarrhenaes, 1.5 parts of Cortex Moutans, 4 parts of Cornu Bubalis, 0.25 part of Cornu rhinocerotis, 2.5 parts of Flos Loniceraes, 1.5 parts of Fructus Forsythiaes, 3.5 parts of Rhizoma Smilacis Glabraes, 1.5 parts of Radix Et Rhizoma Rhei, 0.8 part of Cortex Magnoliae Officinalis, 1 part of Fructus Aurantii Immaturus, 1.4 parts of Rhizoma Alismatis, 4 parts of Herba Artemisiae Scopariaes, 1.5 parts of Semen Arecaes, 1 part of Rhizoma Chuanxiong, 1.4 parts of Thallus Laminariae (Thallus Eckloniae)s, 1.5 parts in Bulbus Allii, 2.5 parts of the Radixs Astragali, 1.4 parts of Radix Codonopsis, 1.6 parts of Radix Angelicae Sinensis, 2.5 parts of Radix Polygoni Multiflori, 2.5 parts in Radix Rehmanniae Preparata, 1.5 parts of Fructus Lycii, 3.5 parts in Fructus Jujubae, 4 parts in Fructus Hordei Germinatus, 1.5 parts of Cordyceps, 2.3 parts of Folium Isatidiss, 2.5 parts of Radix Isatidis, 1.8 parts of Rhizoma Belamcandae, 4 parts of Mel.
7, the medicine of treatment acquired immune deficiency syndrome (AIDS) according to claim 4 is characterized in that 5.5 parts in described Radix Glycyrrhizae, 3.5 parts of Radix Trichosanthis, 2.8 parts of Radix Salviae Miltiorrhizaes, 5.5 parts of Herba Taraxacis, 1 part of Radix Scutellariae, 1.8 parts of Rhizoma Coptidis, 0.6 part of Cortex Phellodendri, 1.8 parts of Fructus Gardeniaes, 0.8 part in Rhizoma Zingiberis Recens, 2.2 parts of the Rhizoma Anemarrhenaes, 2 parts of Cortex Moutans, 5.5 parts of Cornu Bubalis, 0.45 part of Cornu rhinocerotis, 2.8 parts of Flos Loniceraes, 2.8 parts of Fructus Forsythiaes, 6 parts of Rhizoma Smilacis Glabraes, 1.2 parts of Radix Et Rhizoma Rhei, 1.4 parts of Cortex Magnoliae Officinalis, 1 part of Fructus Aurantii Immaturus, 2.2 parts of Rhizoma Alismatis, 2.5 parts of Herba Artemisiae Scopariaes, 2.2 parts of Semen Arecaes, 1.8 parts of Rhizoma Chuanxiongs, 1.6 parts of Thallus Laminariae (Thallus Eckloniae)s, 1.8 parts in Bulbus Allii, 3 parts of the Radixs Astragali, 2.2 parts of Radix Codonopsis, 1.4 parts of Radix Angelicae Sinensis, 3.5 parts of Radix Polygoni Multiflori, 2 parts in Radix Rehmanniae Preparata, 2.1 parts of Fructus Lycii, 5.5 parts in Fructus Jujubae, 3.5 parts in Fructus Hordei Germinatus, 1.3 parts of Cordyceps, 2.8 parts of Folium Isatidiss, 3 parts of Radix Isatidis, 1.4 parts of Rhizoma Belamcandae, 3.5 parts of Mel, 0.045 part of nucleic acid.
8, the medicine of treatment acquired immune deficiency syndrome (AIDS) according to claim 4 is characterized in that 4 parts in described Radix Glycyrrhizae, 5.5 parts of Radix Trichosanthis, 1.5 parts of Radix Salviae Miltiorrhizaes, 3 parts of Herba Taraxacis. 1.8 parts of Radix Scutellariaes, 0.6 part of Rhizoma Coptidis, 0.6 part of Cortex Phellodendri, 1.4 parts of Fructus Gardeniaes, 1.8 parts in Rhizoma Zingiberis Recens, 14 parts of the Rhizoma Anemarrhenaes, 2.2 parts of Cortex Moutans, 3.5 parts of Cornu Bubalis, 0.55 part of Cornu rhinocerotis, 2.2 parts of Flos Loniceraes, 2 parts of Fructus Forsythiaes, 11 parts of Rhizoma Smilacis Glabraes, 1.8 parts of Radix Et Rhizoma Rhei, 1.8 parts of Cortex Magnoliae Officinalis, 1.8 parts of Fructus Aurantii Immaturuss, 1.8 parts of Rhizoma Alismatis, 5.5 parts of Herba Artemisiae Scopariaes, 1.4 parts of Semen Arecaes, 0.8 part of Rhizoma Chuanxiong, 2.2 parts of Thallus Laminariae (Thallus Eckloniae)s, 1.2 parts in Bulbus Allii, 5.5 parts of the Radixs Astragali, 1.8 parts of Radix Codonopsis, 2.8 parts of Radix Angelicae Sinensis, 3 parts of Radix Polygoni Multiflori, 3.5 parts in Radix Rehmanniae Preparata, 1.8 parts of Fructus Lycii, 4 parts in Fructus Jujubae, 5.5 parts in Fructus Hordei Germinatus, 18 parts of Cordyceps, 2.5 parts of Folium Isatidiss, 2.3 parts of Radix Isatidis, 2 parts of Rhizoma Belamcandae, 5.5 parts of Mel, 0.06 part of nucleic acid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021099502A CN1167452C (en) | 2002-01-28 | 2002-01-28 | Medicine for treating AIDS |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021099502A CN1167452C (en) | 2002-01-28 | 2002-01-28 | Medicine for treating AIDS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1367003A true CN1367003A (en) | 2002-09-04 |
| CN1167452C CN1167452C (en) | 2004-09-22 |
Family
ID=4740868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021099502A Expired - Fee Related CN1167452C (en) | 2002-01-28 | 2002-01-28 | Medicine for treating AIDS |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1167452C (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005097148A1 (en) * | 2004-04-09 | 2005-10-20 | Beijing Qijieyuan Pharmaceutical Technology Development Co., Ltd. | Pharmaceutics of traditional chinese medicine of treating aids and preparation method thereof |
| WO2006015556A1 (en) * | 2004-08-12 | 2006-02-16 | Shengxun Tian | A antiviral combination and thereof manufacture |
| CN101411796B (en) * | 2008-12-05 | 2011-09-07 | 中国热带农业科学院热带生物技术研究所 | Novel use of betelnut and extract thereof in preparing anti-AIDS medicament |
| CN102600402A (en) * | 2012-02-01 | 2012-07-25 | 唐福 | Medicine for treating acquired immune deficiency syndrome |
| CN102783645A (en) * | 2012-08-27 | 2012-11-21 | 郑州同心堂生物科技有限公司 | Health care product for enhancing immunity |
| CN103859109A (en) * | 2014-03-18 | 2014-06-18 | 贵州省印江自治县梵净青茶业有限责任公司 | Detoxification anticancer tea and preparation method thereof |
| CN105770431A (en) * | 2016-05-17 | 2016-07-20 | 唐天东 | Traditional Chinese medicine composition for treating AIDS and preparation method thereof |
| CN105998305A (en) * | 2016-06-29 | 2016-10-12 | 李春林 | Disinfection solution and preparation method and application thereof |
| CN108159322A (en) * | 2018-02-10 | 2018-06-15 | 郑小眼 | It is a kind of to treat AIDS urinary system Chinese medicine composition |
| CN108186946A (en) * | 2018-02-10 | 2018-06-22 | 郑小眼 | It is a kind of to treat AIDS skin system Chinese medicine composition |
| US20230141424A1 (en) * | 2021-11-08 | 2023-05-11 | Ying-Chieh Huang | Method for treating hiv/aids complications such as viral encephalopathy, drug-induced encephalopathy, and neurological disorders of immunocompromised concurrent opportunistic infections including motor nerve, sensory nerve and optic nerve disorders |
-
2002
- 2002-01-28 CN CNB021099502A patent/CN1167452C/en not_active Expired - Fee Related
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005097148A1 (en) * | 2004-04-09 | 2005-10-20 | Beijing Qijieyuan Pharmaceutical Technology Development Co., Ltd. | Pharmaceutics of traditional chinese medicine of treating aids and preparation method thereof |
| GB2430370A (en) * | 2004-04-09 | 2007-03-28 | Beijing Qijieyuan Pharmaceutic | Pharmaceutics of traditional chinese medicine of treating aids and preparation method thereof |
| GB2430370B (en) * | 2004-04-09 | 2009-04-01 | Beijing Qijieyuan Pharmaceutic | Chinese medicine preparation for treating AIDS |
| AU2004318154B2 (en) * | 2004-04-09 | 2010-02-18 | Shanghai Hundreds' Ace Herbal Pharmaceutical Co., Ltd | Pharmaceutics of traditional chinese medicine of treating aids and preparation method thereof |
| WO2006015556A1 (en) * | 2004-08-12 | 2006-02-16 | Shengxun Tian | A antiviral combination and thereof manufacture |
| CN101411796B (en) * | 2008-12-05 | 2011-09-07 | 中国热带农业科学院热带生物技术研究所 | Novel use of betelnut and extract thereof in preparing anti-AIDS medicament |
| CN102600402A (en) * | 2012-02-01 | 2012-07-25 | 唐福 | Medicine for treating acquired immune deficiency syndrome |
| CN102600402B (en) * | 2012-02-01 | 2013-10-30 | 唐福 | Medicine for treating acquired immune deficiency syndrome |
| CN102783645B (en) * | 2012-08-27 | 2013-06-05 | 郑州同心堂生物科技有限公司 | Health care product for enhancing immunity |
| CN102783645A (en) * | 2012-08-27 | 2012-11-21 | 郑州同心堂生物科技有限公司 | Health care product for enhancing immunity |
| CN103859109A (en) * | 2014-03-18 | 2014-06-18 | 贵州省印江自治县梵净青茶业有限责任公司 | Detoxification anticancer tea and preparation method thereof |
| CN105770431A (en) * | 2016-05-17 | 2016-07-20 | 唐天东 | Traditional Chinese medicine composition for treating AIDS and preparation method thereof |
| CN105998305A (en) * | 2016-06-29 | 2016-10-12 | 李春林 | Disinfection solution and preparation method and application thereof |
| CN108159322A (en) * | 2018-02-10 | 2018-06-15 | 郑小眼 | It is a kind of to treat AIDS urinary system Chinese medicine composition |
| CN108186946A (en) * | 2018-02-10 | 2018-06-22 | 郑小眼 | It is a kind of to treat AIDS skin system Chinese medicine composition |
| US20230141424A1 (en) * | 2021-11-08 | 2023-05-11 | Ying-Chieh Huang | Method for treating hiv/aids complications such as viral encephalopathy, drug-induced encephalopathy, and neurological disorders of immunocompromised concurrent opportunistic infections including motor nerve, sensory nerve and optic nerve disorders |
| US11730787B2 (en) * | 2021-11-08 | 2023-08-22 | Ying-Chieh Huang | Method for treating HIV/AIDS complications such as viral encephalopathy, drug-induced encephalopathy, and neurological disorders of immunocompromised concurrent opportunistic infections including motor nerve, sensory nerve and optic nerve disorders |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1167452C (en) | 2004-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1485083A (en) | Capsule for thyroid cancer / tumor and lymph node | |
| CN1354014A (en) | Gongbu ointment | |
| CN101361894A (en) | Medicine for treating mastitis | |
| CN101711848B (en) | Chinese medicinal composition capable of adjunctively treating tumour | |
| CN1167452C (en) | Medicine for treating AIDS | |
| CN103800876B (en) | Traditional Chinese medicine for treating obesity | |
| CN101185673A (en) | Medicine for treating nasosinusitis | |
| CN104288412A (en) | Traditional Chinese medicinal composition for treating metabolic syndrome | |
| CN101214296A (en) | Hypertension-treating medicine and preparation thereof | |
| CN101249255B (en) | Proprietary Chinese medicine for curing children's cough and method of preparing the same | |
| CN115282229B (en) | Traditional Chinese medicine composition for treating qi deficiency and blood stasis type coronary heart disease and preparation method thereof | |
| CN104257883A (en) | Traditional Chinese medicine composition for treating leucopenia after chemotherapy | |
| CN103735988A (en) | Traditional Chinese medicinal preparation for treating enterogastritis and preparation method thereof | |
| CN103191312B (en) | Kidney tonifying and body building medicament | |
| CN106511915A (en) | Applications of compound traditional Chinese medicinal composition in preparing medicines for inhibiting skin melanoma lung metastasis | |
| CN1293908C (en) | Cancer preventing and curing Chinese medicine of two snakes and Ganoderma Lucidum seu Japonicum | |
| CN1256976C (en) | Anti-cancer Chinese medicinal composition and its preparing method | |
| CN103127417A (en) | Drug for curing nasosinusitis and preparation method thereof | |
| CN1127968C (en) | Oral powder medicine Xiaobaisan for treating leukotrichia and its preparation method | |
| CN101085185A (en) | Beverage containing white peony root and gardenia | |
| CN102139062A (en) | Novel traditional Chinese medicine for treating pharyngitis and tonsillitis | |
| CN1063074C (en) | Chinese herbs injection for treating oncoma (cancer) and preparation method | |
| CN103721154A (en) | Traditional Chinese medicinal preparation for treating gastrointestinal diseases and preparation method of traditional Chinese medicinal preparation | |
| CN105106633B (en) | A kind of Chinese medicinal capsule for treating gastric ulcer and its complication | |
| CN102008701A (en) | Chinese medicinal composite for treating lung heat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Zhang Zaichun Document name: Notice of publication of the application for patent for invention and examination of the substance of the examination procedure; |
|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Zhang Zaichun Document name: Notification of registration; notice of patent for invention |
|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Zhang Zaichun Document name: Deemed a waiver of a patent claim |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Zhang Zaichun Document name: Patent specification |
|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Zhang Zaichun Document name: Notification to Pay the Fees |
|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Zhang Zaichun Document name: Notification of Termination of Patent Right |
|
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |